BeyondSpring (NASDAQ:BYSI) Shares Down 2.5% – What’s Next?

BeyondSpring Inc. (NASDAQ:BYSI) shares dropped 2.5% during trading on Monday . The stock traded as low as $1.51 and last traded at $1.58. Approximately 21,469 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 50,344 shares. The stock had previously closed at $1.62.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of BeyondSpring in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

BeyondSpring Stock Down 2.5%

The company has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $1.88. The company has a market capitalization of $63.72 million, a price-to-earnings ratio of -10.53 and a beta of 0.55.

Institutional Investors Weigh In On BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC lifted its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 256,212 shares of the company’s stock after buying an additional 231,844 shares during the quarter. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the SEC. Institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.